Cemiplimab in the treatment of non‑melanoma skin tumors

01/2021

Doc. MUDr. David Vrána, Ph.D.

Komplexní onkologické centrum, Nemocnice Nový Jičín

SUMMARY

Non-melanoma skin cancer represents the most frequent cancer overall. Radiotherapy and surgery are the main treatment modalities; however, the best choice depends on tumor location, patient age, comorbidities and also patienťs preference. A small portion of these patients unfortunately progress into locally advanced or metastatic form when surgery and radiotherapy are not possible. Cemiplimab represents another check-point inhibitor molecule (belongs among programmed cell death protein 1 receptor inhibitors [PD-1]) which has proven effectivity and safety in clinical trials for the treatment of locally advancedor metastatic squamous cell and basal cell carcinoma where surgery and radiotherapy are not feasible. Cemiplimab is another reasonable treatment choice for this group of patients since effectivity of conventional chemotherapy is limited.

Key words

non-melanoma skin cancer, squamous cell carcinoma, basal cell carcinoma, cemiplimab